Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BACKGROUND: A newly defined congenital myasthenic syndrome (CMS) caused by DPAGT1 mutations has recently been reported. While many other CMS-associated proteins have discrete roles localised to the neuromuscular junction, DPAGT1 is ubiquitously expressed, modifying many proteins, and as such is an unexpected cause of isolated neuromuscular involvement. METHODS: We present detailed clinical characteristics of five patients with CMS caused by DPAGT1 mutations. RESULTS: Patients have prominent limb girdle weakness and minimal craniobulbar symptoms. Tubular aggregates on muscle biopsy are characteristic but may not be apparent on early biopsies. Typical myasthenic features such as pyridostigmine and 3, 4- diaminopyridine responsiveness, and decrement on repetitive nerve stimulation are present. CONCLUSIONS: These patients mimic myopathic disorders and are likely to be under-diagnosed. The descriptions here should facilitate recognition of this disorder. In particular minimal craniobulbar involvement and tubular aggregates on muscle biopsy help to distinguish DPAGT1 CMS from the majority of other forms of CMS. Patients with DPAGT1 CMS share similar clinical features with patients who have CMS caused by mutations in GFPT1, another recently identified CMS subtype.

Original publication




Journal article


J Neurol Neurosurg Psychiatry

Publication Date





1119 - 1125


Genetics, Molecular Biology, Myasthenia, Myopathy, Neuropathology, Muscle, 4-Aminopyridine, Adrenergic beta-2 Receptor Agonists, Adult, Age of Onset, Albuterol, Amifampridine, Biopsy, Cholinesterase Inhibitors, DNA Mutational Analysis, Diagnosis, Differential, Exome, Female, Genetic Testing, Glycosylation, Humans, Male, Middle Aged, Motor Neurons, Muscle, Skeletal, Myasthenic Syndromes, Congenital, N-Acetylglucosaminyltransferases, Neurologic Examination, Neuromuscular Junction, Phenotype, Potassium Channel Blockers, Pyridostigmine Bromide